Name : DR.

DEEPTI TRIPATHI
Age/Gender : 29 years / Female Ref. Doctor : GOVT DENTAL COLLAGE RAIPUR MEDID : 573663
Sample Type : Serum Collected : 18/04/2025, 01:18 PM
Sample ID : 244733755 Received : 18/04/2025, 01:21 PM
Client Name : 2CGRPR017 Reported : 18/04/2025, 02:19 PM

CLINICAL BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

Lipid Profile
Cholesterol - Total 193 mg/dL <200 : Desirable
(Method: Cholesterol Oxidase, Esterase, peroxidase)
200-239 : Borderline risk
>240 : High risk
Cholesterol - HDL 49 mg/dL < 40 : Low
(Method: Enzymatic Colorimetric)
40 - 60 : Optimal
> 60 : Desirable
Cholesterol - LDL 123.80 mg/dL < 100 : Normal
(Method: Enzymatic Colorimetric)
100 - 129 : Desirable
130 – 159 : Borderline-High
160 – 189 : High
> 190 : Very High
Cholesterol VLDL 20.20 mg/dL 7 - 40
(Method: Calculated)
Triglycerides 101 mg/dL < 150 :Normal
(Method: Lipase / Glycerol Kinase)
150–199 :Borderline-High
200–499 :High
> 500 :Very High
Cholesterol - Non-HDL 144 mg/dL < 130 mg/dl: Desirable
(Method: Calculated)
Total cholesterol/HDL 3.94 Ratio 0 - 5.0
(Method: Calculated)
LDL / HDL 2.53 Ratio 0 - 3.5
(Method: Calculated)
Interpretation:
• For non-fasting samples, the biological reference interval remains the same for all parameters, except of triglyceride as cholesterol (HDL, LDL, total), which changes

only by a small amount in the non-fasting state; the recommended desired value for triglyceride is <175 mg/dl. In the non-sting state, individuals with a non-fasting

triglyceride level >200 mg/dl, are recommended to perform a follow-up fasting lipid panel in 2 to 4 weeks.

• As per the consensus of the Lipid Association of India, non-HDL cholesterol and LDL cholesterol can be used as targets to monitor the effectiveness of lipid-lowering

therapy.

Associated tests: Apolipoproteins A1, Apolipoproteins B, Apolipoprotein B/A1 Ratio, Lipoprotein(a)

**END OF REPORT**

This is an electronically authenticated report. Report Printed Date: 18/04/2025, 04:07 PM

NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 1 of 12
Name : DR. DEEPTI TRIPATHI
Age/Gender : 29 years / Female Ref. Doctor : GOVT DENTAL COLLAGE RAIPUR MEDID : 573663
Sample Type : Serum Collected : 18/04/2025, 01:18 PM
Sample ID : 244733755 Received : 18/04/2025, 01:21 PM
Client Name : 2CGRPR017 Reported : 18/04/2025, 02:19 PM

BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

Liver Function Profile

Bilirubin Total 0.5 mg/dL 0 - 1.0
(Method: Diazo Method)
Bilirubin Direct 0.2 mg/dL 0 - 0.3
(Method: Diazo method)
Bilirubin Indirect 0.30 mg/dL 0 - 1.0
(Method: Calculated)
Alkaline Phosphatase (ALP) 126 U/L 50 - 136
(Method: PNPP, AMP Buffer)
Alanine Transaminase (ALT/SGPT) 13 U/L Upto 33
(Method: UV without pyridoxal -5- phosphate)
Aspartate Aminotransferase(AST/SGOT) 20 U/L Upto 32
(Method: IFCC Without Pyridoxal Phosphate)
Y- Glutamyl Transferase (GGT) 17 U/L 5 - 36
(Method: glutamyl-carboxynitroanilide)
Protein Total 8.2 g/dL 6.4 - 8.3
(Method: Biuret)
Albumin 4.4 g/dL 3.5 - 5.4
(Method: Bromcresol Green)
Globulin 3.80 g/dl 2.5 - 3.5
(Method: Calculated)
Albumin/Globulin 1.16 Ratio 1.0 - 2.1
(Method: Calculated)
Interpretation:
LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity(AST & ALT),synthesis and secretion of bile (Bilirubin ,ALP),cholestasis (ALP,GGT),protein synthesis (Albumin).
1. Hepatocellular injury:
• AST-Elevated levels can be seen. However,it is not specific to liver and can be raised in cardiac and skeletal injuries.
• ALT -Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury.
Values also correlate well with increasing BMI.
• Disproportinate increase in AST,ALT compared with ALP.
• Bilirubin may be elevated.
• AST: ALT (ratio) - In case of hepatocellular injury AST : ALT >1
In Alcoholic Liver Disease AST : ALT usually >2
This ratio is also seen to be increased in NAFLD ,Wilsons's disease, Cirrhosis ,but the increase is usually not >2
2. Cholestatic pattern:
• ALP - Disproportinate increase in ALP compared with AST,ALT.
• Bilirubin may be elevated.
• ALP elevation also seen in pregnancy,impacted by age and sex.
• To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.
3. Synthesis function impairment:
• Albumin - Liver disease reduces albumin levels. Correlation with PT (Prothrombin Time ) helps.

**END OF REPORT**

This is an electronically authenticated report. Report Printed Date: 18/04/2025, 04:07 PM

NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 2 of 12
Name : DR. DEEPTI TRIPATHI
Age/Gender : 29 years / Female Ref. Doctor : GOVT DENTAL COLLAGE RAIPUR MEDID : 573663
Sample Type : Serum Collected : 18/04/2025, 01:18 PM
Sample ID : 244733755 Received : 18/04/2025, 01:21 PM
Client Name : 2CGRPR017 Reported : 18/04/2025, 02:25 PM

BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

Creatinine 0.7 mg/dL 0.5 - 1.0
(Method: Jaffe Kinetic)
Urea 15 mg/dL Upto 50
(Method: Urease)
Blood Urea Nitrogen (BUN) 7.01 mg/dL 7 - 18
(Method: Calculated)
Blood Urea Nitrogen (BUN)/Creatinine 10.01 Ratio 6 - 22
(Method: Calculated)
Sodium 136 mmol/L 135 - 145
(Method: ISE)
Potassium 3.5 mmol/L 3.8 - 5.2
(Method: ISE)
Chloride 104 mmol/L 94 - 108
(Method: ISE)
Uric Acid 4.0 mg/dL 2.4 - 6.6
(Method: Uricase)
Glomerular Filtration Rate (eGFR) 119.90 mL/min 90 - 120 mL/min/1.73 m2
(Method: Calculated)
Interpretation:
Creatinine: Muscles produce creatinine, a waste product, from creatine phosphate, a substance that stores a lot of energy. Unlike urea, the amount of
creatinine generated is constant and mostly depends on muscle mass. Age, gender, race, muscularity, exercise, pregnancy, and several other
physiulogical characteristics can all have an impact on serum creatinine levels. Decreased serum Creatinine is associated with increasing Age and poor
muscle mass, such as muscular atrophy. Both acute and chronic renal disease and blockage are associated with elevated blood creatinine levels.
Creatinine is not an appropriate indicator for identifying kidney disease in its early stages since an increase in blood creatinine is only seen when there is
significant nephron damage.
High Urea, Uric Acid, and Blood Urea Nitrogen (BUN) could indicate poor renal function, in addition to other etiulogies
Sodium:
• Low levels: prulonged vomiting or diarrhea, diminished reabsorption in the kidney, and excessive fluid retention. Pseudo-hyponatremia is a
laboratory artifact. It is usually caused by hypertriglyceridemia, chulestasis (lipoprotein X), and hyperproteinemia (monoclonal gammopathy,
intravenous immunoglobulin [IVIG]). Diluted sampling should also be suspected in such cases and confirmed on a repeat fresh sample if indicated
clinically.
• High levels: excessive fluid loss, high salt intake, and increased kidney reabsorption.
Potassium:
• Low levels: reduced intake of dietary potassium or excessive loss of potassium from the body due to diarrhea, prulonged vomiting, or increased
renal excretion.
• High levels: dehydration or shock, severe burns, hemulysis, diabetic ketoacidosis, and retention of potassium by the kidney. Pseudohyperkalemia,
which may result from a hemulyzed or aged sample, should always be ruled out by doing a repeat electrulyte estimation on a fresh
sample, as clinically indicated.
Chloride:
• Low levels are noted in reduced dietary intake, prulonged vomiting, and reduced renal reabsorption, as well as some forms of acidosis and alkalosis.
• High levels are found in dehydration, kidney failure, some forms of acidosis, high dietary or parenteral chloride intake, and salicylate poisoning
An estimated glomerular filtration rate (eGFR) test is an indicator of how well kidneys filter waste and toxins from blood.

**END OF REPORT**

This is an electronically authenticated report. Report Printed Date: 18/04/2025, 04:07 PM

NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 3 of 12
Name : DR. DEEPTI TRIPATHI
Age/Gender : 29 years / Female Ref. Doctor : GOVT DENTAL COLLAGE RAIPUR MEDID : 573663
Sample Type : Serum Collected : 18/04/2025, 01:18 PM
Sample ID : 244733755 Received : 18/04/2025, 01:21 PM
Client Name : 2CGRPR017 Reported : 18/04/2025, 02:18 PM

BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

IRON PROFILE
Iron 30 µg/dL 33 - 193
(Method: Ferrozine – without Deproteinization)
UIBC 413 µg/dL 155 - 355
(Method: Nitroso-PSAP)
Iron Binding Capacity - Total (TIBC) 443 µg/dL 240 - 450
(Method: Calculated)
Transferrin % 6.77 % 20 - 50
(Method: Calculated)
Interpretation:
%Transferrin
Disease Iron TIBC UIBC Ferritin
Saturation

Iron Deficiency Low High High Low Low

Hemochromatosis High Low Low High High

Chronic Illness Low Low Low/Normal Low Normal/High

Hemolytic Anemia High Normal/Low Low/Normal High High

Sideroblastic
Normal/High Normal/Low Low/Normal High High
Anemia

Iron Poisoning High Normal Low High Normal

**END OF REPORT**

This is an electronically authenticated report. Report Printed Date: 18/04/2025, 04:07 PM

NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 4 of 12
Name : DR. DEEPTI TRIPATHI
Age/Gender : 29 years / Female Ref. Doctor : GOVT DENTAL COLLAGE RAIPUR MEDID : 573663
Sample Type : Serum Collected : 18/04/2025, 01:18 PM
Sample ID : 244733755 Received : 18/04/2025, 01:21 PM
Client Name : 2CGRPR017 Reported : 18/04/2025, 02:35 PM

IMMUNOLOGY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

Thyroid Profile-II
Triiodothyronine Total (TT3) 124.15 ng/dL 126 – 258: 1 Yr – 5 Yr
(Method: CLIA)
96 – 227: 6 Yr – 15 Yr
91 – 164: 16 Yr – 18 Yr
60 – 181 : > 18 years
Pregnancy:
1st Trimester: 81 - 190
2nd & 3rd Trimester:100 - 260
Triiodothyronine Free (FT3) 3.56 pg/mL 2.3 - 4.2
(Method: CLIA)
2.0 - 3.8: Pregnancy
Thyroxine - Total (TT4) 8.49 ug/dL 4.6 - 10.9
(Method: CLIA)
Pregnancy:
4.6 – 16.5: 1st Trimester
4.6 – 18.5: 2nd & 3rd Tri
Thyroxine - Free (FT4) 1.42 ng/dL 0.8 - 2.7: Adults
(Method: CLIA)
Pregnancy
0.7 - 2.0: First Trimester
0.5 - 1.6: 2nd and 3rd Tri
Thyroid Stimulating Hormone (TSH) 3.01 uIU/mL 0.46 – 8.10 : 1 Yrs – 5 Yrs
(Method: CLIA)
0.36 – 5.80 : 6 Yrs – 18 Yrs
0.35 – 5.50 : 18 Yrs – 55 Yrs
0.50 – 8.90 : >55 yrs
Pregnancy Ranges
Ist Tri:0.1 - 2.5
IInd Tri:0.2 - 3.0
IIIrd Tri:0.3 - 3.0
Interpretation:
Important Note:

A TSH value of up to 15 µIU/ml needs clinical correlation or repeat testing with a new sample, as physiological factors can give falsely high TSH.

Transiently Raised TSH can occur due to non-thyroid illnesses like severe infections liver, cardiac, and kidney diseases, burns, surgery, and trauma.

Diurnal Variability: TSH Follows a Diurinal rhythm and is at maximum between 2 am to 4 am and a minimum between 6 to 10 pm. Variation is about

50-206%.

Limitations:
• Patients receiving High Biotin Dose treatment should have a gap of a minimum of 8 hrs, before giving the blood sample.

This is an electronically authenticated report. Report Printed Date: 18/04/2025, 04:07 PM

NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 5 of 12
Name : DR. DEEPTI TRIPATHI
Age/Gender : 29 years / Female Ref. Doctor : GOVT DENTAL COLLAGE RAIPUR MEDID : 573663
Sample Type : Serum Collected : 18/04/2025, 01:18 PM
Sample ID : 244733755 Received : 18/04/2025, 01:21 PM
Client Name : 2CGRPR017 Reported : 18/04/2025, 02:35 PM

IMMUNOLOGY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

• Heterophile Antibodies can react in Immunoassay procedures giving erroneous results. The assay is designed to minimize heterophile antibody
interference.
Please Note: FT3 and FT4 Measure the free "unbound" fraction of the T3 and T4 and are considered more sensitive compared to the Total T3 and T4 to

assess thyroid status.

Associated tests: Anti-thyroid Antibodies, USG thyroid, TSH receptor Antibody. Thyroglobulin, Calcitonin.

**END OF REPORT**

This is an electronically authenticated report. Report Printed Date: 18/04/2025, 04:07 PM

NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 6 of 12
Name : DR. DEEPTI TRIPATHI
Age/Gender : 29 years / Female Ref. Doctor : GOVT DENTAL COLLAGE RAIPUR MEDID : 573663
Sample Type : WB EDTA* Collected : 18/04/2025, 01:18 PM
Sample ID : 244733756 Received : 18/04/2025, 01:21 PM
Client Name : 2CGRPR017 Reported : 18/04/2025, 02:45 PM

CLINICAL BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

Glycosylated Hemoglobin (GHb/HBA1c)

HbA1c 5.6 % < 6.0 : Non Diabetic
(Method: HPLC)
6.1 – 6.5 : Prediabetic
6.6 – 7.0 : Good Control
7.1-8.0 : POOR Control
>8.1 : ALERT
Estimated Average Glucose (eAG) 114.02 mg/dL 70 - 136
Interpretation:
Excellent Control: 6 to 7 %

Fair to Good Control: 7 to 8 %

Unsatisfactory Control: 8 to 10 %

and Poor Control: More than 10%.

Factors Influencing HbA1c Results: Increased levels: Elevated fetal hemoglobin, chronic renal failure, iron deficiency anemia, splenectomy,

heightened serum triglycerides, alcohol consumption, poisoning (Lead, Opiate), and salicylate therapy. Decreased levels: are often associated with

systemic inflammatory diseases and reduced RBC life span, severe iron deficiency & haemolytic anaemia, chronic renal failure, and liver diseases.

Clinical correlation reduced red blood cell lifespan (such as in hemolytic anemia or blood loss), following blood transfusions, during pregnancy, excessive

intake of Vitamin E or Vitamin C, and hemoglobinopathies, For HbF > 25% and homozygous hemoglobinopathy, an alternate platform (Fructosamine) is

recommended for testing of HbA1c.

• HbA1c, also known as glycosylated hemoglobin or glycated hemoglobin, refers to hemoglobin that has glucose molecules attached. It gives an

average of glucose levels in the bloodstream for the preceding 2 to 3 months.

• HbA1c has been endorsed by clinical groups & ADA (American Diabetes Association) guidelines for the diagnosis of diabetes using a cut-off point of

6.5%.

• For diabetic patients achieving treatment objectives, the HbA1c test should be conducted at least biannually. If treatment objectives are not met or if

a new regimen is initiated, testing once every 3 months is recommended.

• The HbA1c target for non-pregnant adults is generally set at below 7% to prevent microvascular complications.

• In known diabetic patients, the following values can be considered as a tool for monitoring glycemic control.

Associated tests: HOMA IR index, insulin, C-peptide levels.

**END OF REPORT**

This is an electronically authenticated report. Report Printed Date: 18/04/2025, 04:07 PM

NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 7 of 12
Name : DR. DEEPTI TRIPATHI
Age/Gender : 29 years / Female Ref. Doctor : GOVT DENTAL COLLAGE RAIPUR MEDID : 573663
Sample Type : WB EDTA* Collected : 18/04/2025, 01:18 PM
Sample ID : 244733756 Received : 18/04/2025, 01:21 PM
Client Name : 2CGRPR017 Reported : 18/04/2025, 02:35 PM

HAEMATOLOGY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

Complete Blood Count + ESR

Hemoglobin (Hb) 11.5 g/dL 12.0 - 15.0
(Method: Photometry)
Erythrocyte Count (RBC Count) 4.46 mil/µL 3.8 - 4.8
(Method: Electronic Impedance)
PCV (Hematocrit) 33.9 % 35 - 47
(Method: Calculated)
Platelet Count 3.43 lakh/Cumm 1.5 - 4.0
(Method: Electronic Impedance)
Red cell Indices
(Method: Calculated/Automated 5-Part Cell Counter)
MCV 76.0 fl 83 - 101
MCH 25.9 pg 27 - 32
MCHC 34.0 g/dL 31.5 - 34.5
RDW - CV 18.6 % 11.5 - 14.5
Total and Differential count
(Method: Impdedance and light scattering/Microscopy/Automated
5-Part Cell Counter)
WBC Count 14220 cells/Cumm 4000 - 11000
Neutrophils 78 % 40 - 80
Lymphocytes 15 % 20 - 40
Eosinophils 02 % 1-6
Monocytes 05 % 2 - 10
Basophils 00 % 0-1
Erythrocyte Sedimentation Rate (ESR) 28 mm/Hour <12
(Method: Westergren's)
Pregnancy first trimester : < 48
Pregnancy Second trimester : < 70
**END OF REPORT**

This is an electronically authenticated report. Report Printed Date: 18/04/2025, 04:07 PM

NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 8 of 12
Name : DR. DEEPTI TRIPATHI
Age/Gender : 29 years / Female Ref. Doctor : GOVT DENTAL COLLAGE RAIPUR MEDID : 573663
Sample Type : Serum Collected : 18/04/2025, 01:18 PM
Sample ID : 244733755 Received : 18/04/2025, 01:21 PM
Client Name : 2CGRPR017 Reported : 18/04/2025, 02:18 PM

CLINICAL BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

Calcium & Phosphorus

Calcium 9.6 mg/dL 8.6 - 10.3
(Method: NM-Bapta complex)
Interpretation:
The diagnosis and monitoring of a wide range of disorders including diseases of bone, kidney, parathyroid gland, or gastrointestinal
tract Calcium levels may also reflect abnormal vitamin D or protein levels. Calcium ions affect the contractility of the heart and the
skeletal musculature, and are essential for the function of the nervous system. In addition, calcium ions play an important role in
blood clotting and bone mineralization.
Hypocalcemia is due to the absence or impaired function of the parathyroid glands or impaired vitamin-D synthesis. Chronic renal
failure is also frequently associated with hypocalcemia due to decreased vitamin-D synthesis as well as hyperphosphatemia and
skeletal resistance to the action of parathyroid hormone (PTH). A characteristic symptom of hypocalcemia is latent or manifest
tetany and osteomalacia.

Phosphorus 3.0 mg/dL 2.5 - 4.5

(Method: Phosphomolybdate - UV)

**END OF REPORT**

This is an electronically authenticated report. Report Printed Date: 18/04/2025, 04:07 PM

NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 9 of 12
Name : DR. DEEPTI TRIPATHI
Age/Gender : 29 years / Female Ref. Doctor : GOVT DENTAL COLLAGE RAIPUR MEDID : 573663
Sample Type : Serum Collected : 18/04/2025, 01:18 PM
Sample ID : 244733755 Received : 18/04/2025, 01:21 PM
Client Name : 2CGRPR017 Reported : 18/04/2025, 03:07 PM

CLINICAL BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

Folic Acid, Vitamin - B12 & 25-Hydroxy Vitamin D Total (D2 & D3)

Folate Serum (Folic Acid) 6.35 ng/mL 4 - 11 Years: 8.6 - 37.7

(Method: CLIA)
12 -19 Years: 5.0 - 27.2
20 - 59 Years: 4.4 - 31.0
>60 Years: 5.6 - 45.8

Vitamin - B12 91 pg/mL 120 - 980

(Method: CLIA)

25-Hydroxy Vitamin D Total (D2 & D3) 3.04 ng/mL 30 - 70

(Method: CLIA)

Interpretation:
Levels Reference Range

Deficiency ( serious deficient ) < 20 ng/ml

Insufficiency ( Deficient ) 20 - 30 ng/ml

Sufficient ( adequate ) 30 - 100 ng/ml

Toxicity > 100 ng/ml

Decreased Levels

• Deficiency in children causes Rickets and Osteomalacia. It can also lead to Hypocalcemia and Tetany.

• Inadequate exposure to sunlight.

• Dietary deficiency.

• Vitamin D malabsorption.

• Severe Hepatocellular disease.

• Drugs like Anticonvulsants.

• Nephrotic syndrome.

Increased Levels

• Vitamin D intoxication.

Note:Vitamin D levels may vary according to factors such as geography, season, or the patient’s health, diet, age, ethnic origin, use of vitamin D supplementation or

environment.

This is an electronically authenticated report. Report Printed Date: 18/04/2025, 04:07 PM

NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 10 of 12
Name : DR. DEEPTI TRIPATHI
Age/Gender : 29 years / Female Ref. Doctor : GOVT DENTAL COLLAGE RAIPUR MEDID : 573663
Sample Type : Serum Collected : 18/04/2025, 01:18 PM
Sample ID : 244733755 Received : 18/04/2025, 01:21 PM
Client Name : 2CGRPR017 Reported : 18/04/2025, 03:07 PM

CLINICAL BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

**END OF REPORT**

This is an electronically authenticated report. Report Printed Date: 18/04/2025, 04:07 PM

NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 11 of 12
Name : DR. DEEPTI TRIPATHI
Age/Gender : 29 years / Female Ref. Doctor : GOVT DENTAL COLLAGE RAIPUR MEDID : 573663
Sample Type : Urine Collected : 18/04/2025, 01:18 PM
Sample ID : 244733757 Received : 18/04/2025, 01:20 PM
Client Name : 2CGRPR017 Reported : 18/04/2025, 02:08 PM

CLINICAL PATHOLOGY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

Complete Urine Analysis (CUE)

(Method: Strip/Microscopy)
Color REDDISH -
Appearance Slightly Hazy -
Specific gravity 1.010 1.000 - 1.030
Reaction (pH) 5.0 5.0 - 8.5
Proteins Positive (+) Negative
Glucose Negative Negative
Bile salts & Bile pigments Negative Negative
Ketones Negative Negative
Blood Positive Negative
Urobilinogen Normal Normal
Nitrites Negative Negative
PUS(WBC) Cells 12-15 0 - 5 /HPF
Urine RBC 8-10 NIL
U.Epithelial Cells 4-6 0 - 5/HPF
Casts & Crystals Absent NIL
Others Nil Nil
**END OF REPORT**

This is an electronically authenticated report. Report Printed Date: 18/04/2025, 04:07 PM

NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 12 of 12